epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove Hadlima (adalimumab-bwwd)
    adalimumab
  • remove Otulfi (ustekinumab-aauz)
    ustekinumab
  • remove Wezlana (ustekinumab-auub)
    ustekinumab

multicheck MultiCheck Results - 2 Interactions

Smiley face Smiley face

Avoid/Use Alternative

Smiley face Smiley face Hadlima (adalimumab-bwwd) (adalimumab) + Otulfi (ustekinumab-aauz) (ustekinumab)

Avoid/Use Alternative


adalimumab + ustekinumab

avoid combo: combo may incr. risk of serious infection (additive effects)

Smiley face Smiley face Hadlima (adalimumab-bwwd) (adalimumab) + Wezlana (ustekinumab-auub) (ustekinumab)

Avoid/Use Alternative


adalimumab + ustekinumab

avoid combo: combo may incr. risk of serious infection (additive effects)

Additional Considerations

Smiley face Smiley face adalimumab in Hadlima (adalimumab-bwwd)

caution advised with narrow therapeutic index drugs; chronic inflammatory conditions may alter metabolic enzyme formation; tx with immune modulators may reverse this effect, resulting in altered levels of concomitant drugs

Smiley face Smiley face ustekinumab in Otulfi (ustekinumab-aauz), Wezlana (ustekinumab-auub)

caution advised w/ narrow therapeutic index drugs; chronic inflammatory conditions may alter metabolic enzyme formation; tx w/ immune modulators may reverse this effect, resulting in altered levels of concomitant drugs

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information